Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention [PDF]
Upsala Journal of Medical Sciences, 2020 In this review the advantages of the gonadotropin-releasing hormone agonist (GnRHa) trigger are discussed beyond those immediately associated with ovarian hyperstimulation syndrome (OHSS) prevention.
Juan Carlos Castillo +3 more
doaj +4 more sources
Gonadotropin-releasing hormone agonist-induced pituitary apoplexy [PDF]
Endocrinology, Diabetes & Metabolism Case Reports, 2016 Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences. Drug-induced pituitary apoplexy is a rare but important consideration when evaluating patients with this presentation.
Fergus Keane +4 more
doaj +3 more sources
Pituitary Apoplexy Following Gonadotropin‐Releasing Hormone Agonist Administration for Prostate Cancer [PDF]
IJU Case ReportsIntroduction Pituitary apoplexy represents an uncommon endocrine emergency with potentially life‐threatening consequences. Gonadotropin‐releasing hormone agonist used for prostate cancer has the potential to induce pituitary apoplexy, particularly in the
Masaaki Fujimura +5 more
doaj +2 more sources
Gonadotropin-releasing hormone agonist contributes to the successful implementation of in vitro fertilization in a patient with cervical endometriosis: a case report [PDF]
AJOG Global Reports, 2023 This is a case report of a nulliparous young woman who suffered from prolonged menstruation and infertility for 1 year. Magnetic resonance imaging and a transvaginal ultrasound examination revealed cervical endometriosis.
Turui Yang, MD +4 more
doaj +2 more sources
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study [PDF]
Fertility and Sterility, 2016 To determine the optimal GnRH agonist dose for triggering of oocyte maturation in oocyte donors.Single-center, randomized, parallel, investigator-blinded trial.IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).Ovulation trigger with 0.
Thi Ngoc Lan Vuong +5 more
openaire +4 more sources
Comparison between the modified long gonadotropin-releasing hormone agonist protocol and the non-downregulation protocol in POSEIDON groups: a propensity score matching retrospective cohort study [PDF]
Frontiers in Endocrinology, 2023 BackgroundIn vitro fertilization (IVF) is the main technique to address the infertility issue in the patient-oriented strategy encompassing individualized oocyte number (POSEIDON) population.
Chunyan Chen +5 more
doaj +2 more sources
Basic understanding of gonadotropin-releasing hormone–agonist triggering
Fertility and Sterility, 2015 A single bolus of human chorionic gonadotropin (hCG) at midcycle has been the gold standard for triggering final oocyte maturation and ovulation in assisted reproductive technology cycles. More recently, gonadotropin-releasing hormone (GnRH)-agonist (GnRH-a) triggering has been introduced.
R. Casper
openaire +3 more sources
International Journal of Reproductive BioMedicine, 2018 Background: The use of embryo cryopreservation excludes the possible detrimental effects of ovarian stimulation on the endometrium, and higher reproductive outcomes following this policy have been reported.
Abbas Aflatoonian +10 more
doaj +2 more sources
Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls [PDF]
International Journal of Endocrinology and Metabolism, 2015 Depot preparations of gonadotropin-releasing hormone agonists (GnRHa) are the gold standard drugs for the treatment of central precocious puberty. A concern about these drugs is obesity.This study aimed to investigate the effect of gonadotropin-releasing hormone agonists (GnRHa) therapy on body mass index (BMI) in girls with central precocious puberty (
Shiasi Arani, Kobra, Heidari, Fatemeh
openaire +3 more sources
Effects of gonadotropin-releasing hormone agonist treatment on final adult height in boys with idiopathic central precocious puberty [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2021 Purpose There are few reports on the therapeutic effects of gonadotropin-releasing hormone agonists in boys with central precocious puberty, and studies reported in Korea are very rare.
Ah Young Cho +3 more
doaj +1 more source